CRISPR Therapeutics (NASDAQ:CRSP) had its target price dropped by stock analysts at Oppenheimer from $185.00 to $172.00 in a research note issued to investors on Thursday, The Fly reports. The brokerage currently has an "outperform" rating on the stock. Oppenheimer's price objective would indicate a potential upside of 84.85% from the stock's current price.
CRSP has been the topic of several other research reports. Stifel Nicolaus dropped their target price on CRISPR Therapeutics from $139.00 to $101.00 and set a "hold" rating on the stock in a research report on Wednesday, October 13th. Canaccord Genuity raised their price objective on CRISPR Therapeutics from $151.00 to $160.00 and gave the stock a "buy" rating in a research report on Monday, August 16th. SVB Leerink initiated coverage on CRISPR Therapeutics in a research report on Tuesday, October 19th. They issued an "outperform" rating and a $126.00 price objective for the company.
TheStreet raised CRISPR Therapeutics from a "d" rating to a "c+" rating in a research report on Monday, August 9th. Finally, William Blair reissued a "buy" rating on shares of CRISPR Therapeutics in a research report on Wednesday, October 13th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of "Buy" and an average target price of $159.71.
NASDAQ:CRSP traded down $3.83 during midday trading on Thursday, hitting $93.05. The stock had a trading volume of 36,098 shares, compared to its average volume of 1,828,823. CRISPR Therapeutics has a one year low of $88.29 and a one year high of $220.20. The company has a market capitalization of $7.09 billion, a price-to-earnings ratio of 18.51 and a beta of 2.09. The stock has a 50-day moving average of $109.83 and a 200 day moving average of $120.00.
CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 2nd. The company reported ($1.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.75) by $0.08. CRISPR Therapeutics had a return on equity of 24.08% and a net margin of 49.52%. As a group, research analysts predict that CRISPR Therapeutics will post 4.75 EPS for the current year.
In related news, CFO Michael John Tomsicek sold 25,000 shares of CRISPR Therapeutics stock in a transaction dated Friday, August 6th. The stock was sold at an average price of $138.52, for a total value of $3,463,000.00. Following the completion of the transaction, the chief financial officer now owns 26,891 shares in the company, valued at approximately $3,724,941.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 10.70% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in CRISPR Therapeutics by 1,788.8% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 97,142 shares of the company's stock worth $15,726,000 after buying an additional 91,999 shares during the last quarter. Capital Investment Advisory Services LLC boosted its holdings in shares of CRISPR Therapeutics by 9.0% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 22,613 shares of the company's stock worth $3,661,000 after purchasing an additional 1,858 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of CRISPR Therapeutics by 15.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 45,433 shares of the company's stock worth $7,355,000 after purchasing an additional 6,066 shares during the last quarter. Advisory Services Network LLC boosted its holdings in shares of CRISPR Therapeutics by 22.2% during the 1st quarter. Advisory Services Network LLC now owns 10,158 shares of the company's stock worth $1,238,000 after purchasing an additional 1,848 shares during the last quarter. Finally, CIBC World Markets Inc. boosted its holdings in shares of CRISPR Therapeutics by 177.7% during the 2nd quarter. CIBC World Markets Inc. now owns 11,678 shares of the company's stock worth $1,891,000 after purchasing an additional 7,472 shares during the last quarter. Institutional investors own 51.83% of the company's stock.
About CRISPR Therapeutics
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
Featured Story: What is systematic risk?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here